文献速递皮肤肿瘤

肾移植受者中人类白细胞抗原类型与角质形成细胞癌风险的关联

Association between Human Leukocyte Antigen Type and Keratinocyte Carcinoma Risk in Renal Transplant Recipients.
PubMed 文献 · J Invest Dermatol · 2019-10-24

该研究基于1993-2017年单中心617例白人非西班牙裔肾移植受者队列,分析移植前分子HLA类型与移植后角质形成细胞癌(KC)风险的关联。多变量Cox回归显示HLA-DRB1*13与KC风险(HR 1.84,95%CI 1.00-3.38)及鳞状细胞癌风险(HR 2.24,95%CI 1.12-4.49)相关,HLA-DRB1*14与基底细胞癌风险相关(HR 2.81,95%CI 1.14-6.91)。提示特定HLA多态性的肾移植受者KC风险可能增加。

要点

  • HLA-DRB1*13与肾移植后KC及鳞状细胞癌风险升高相关。
  • HLA-DRB1*14与肾移植后基底细胞癌风险升高相关。
  • 特定HLA类型或可辅助识别KC高危肾移植受者。

核心结论

  • 特定HLA多态性的肾移植受者可能具有更高的角质形成细胞癌风险。

研究设计与样本

  • 基于1993-2017年单中心白人非西班牙裔肾移植受者队列,共617例(平均年龄53岁,67%男性)。
  • 采用Cox比例风险回归模型估计HLA类型与 incident KC、鳞状细胞癌及基底细胞癌的风险比,并调整年龄、男性性别、KC病史、Charlson合并症指数、HLA错配、移植类型、移植年份及免疫抑制类型。

主要发现

  • 617例受者中10%发生移植后KC。
  • HLA-DRB1*13与KC风险相关(HR 1.84;95%CI 1.00-3.38),与鳞状细胞癌风险相关(HR 2.24;95%CI 1.12-4.49)。
  • HLA-DRB1*14与基底细胞癌风险相关(HR 2.81;95%CI 1.14-6.91)。

临床怎么用

  • 对于携带HLA-DRB1*13或HLA-DRB1*14的肾移植受者,可考虑加强皮肤癌筛查与随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Keratinocyte carcinoma (KC), defined as squamous cell carcinoma and basal cell carcinoma, is the most common malignancy among white, non-Hispanic renal transplant recipients. Although recent genome-wide association studies reported that class II HLA is associated with KC risk, epidemiologic data on HLA type and KC risk in renal transplant recipients is limited. Using an institutional cohort of white, non-Hispanic renal transplant recipients transplanted between 1993 and 2017, we examined the association between pretransplant molecular HLA types and KC risk. Posttransplant KCs were captured using the International Classification of Diseases codes and validated using pathology reports. Cox proportional hazards regression models were used to estimate hazard ratios of incident KC, squamous cell carcinoma, and basal cell carcinoma, adjusting for age, male sex, history of KC, Charlson comorbidity index, HLA mismatch, transplant type, year of transplant, and the type of immunosuppression. Among 617 subjects (mean age 53 years, 67% male), 10% developed posttransplant KC. Multivariable Cox regression analyses showed HLA-DRB1∗13 was associated with KC risk (hazard ratio, 1.84; 95% confidence interval, 1.00-3.38) and squamous cell carcinoma risk (hazard ratio, 2.24; 95% confidence interval, 1.12-4.49), whereas HLA-DRB1∗14 (hazard ratio, 2.81; 95% confidence interval, 1.14-6.91) was associated with basal cell carcinoma risk. Our findings suggest that a subset of renal transplant recipients with specific HLA polymorphisms may be at increased KC risk.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Kim Y, Wojciechowski D, Pattanayak V, et al. Association between Human Leukocyte Antigen Type and Keratinocyte Carcinoma Risk in Renal Transplant Recipients. J Invest Dermatol. 2019. PMID: 31669059. doi:10.1016/j.jid.2019.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。